I’ve always felt strongly about the power in collaboration and connections to drive growth. When I joined Orchard as VP, Global Head of Pharmacovigilance in January 2020, I was ini...

In my last post, I shared my perspective on the overall field of gene therapy and the distinctive characteristics of the hematopoietic stem cell (HSC) gene therapy approach that Or...

I feel very fortunate to have spent the past three decades and almost my entire professional career in the field of gene therapy, helping to shape its growth from what many people...

The past year was one of tremendous challenges and changes, and it served as a resounding reminder that our health cannot be taken for granted. For our team at Orchard, this year a...

The process of making personalized gene therapies is arguably the most complex pharmaceutical manufacturing process of any medicine to date. For hematopoietic stem cell (HSC) gene...